MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that it closed an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The shares of common stock commenced trading on the Nasdaq Capital Market on August 15, 2025, under ...

Core Points - Propanc Biopharma, Inc. is set to begin trading on Nasdaq under the symbol PPCB after pricing an underwritten public offering of 1,000,000 shares at $4.00 per share, expected to yield approximately $4 million in gross proceeds [1][2] - The offering is anticipated to close on August 18, 2025, and includes a 45-day option for the underwriter to purchase an additional 150,000 shares [2][3] - The company’s shares were previously quoted on the OTC Markets, Pink Tier, and will cease to be quoted as of August 14, 2025, with no action required from stockholders [3] Company Overview - Propanc Biopharma, Inc. is focused on developing novel cancer treatments aimed at preventing recurrence and metastasis of solid tumors, specifically targeting pancreatic, ovarian, and colorectal cancers [6][7] - The company’s therapy utilizes pancreatic proenzymes to target and eradicate cancer stem cells, leveraging the body's natural defense mechanisms against cancer [6][7]